TENX Live signals | Maximize Profits with Getagraph.com

BUY 91177 min ago

@ $4.72

Issued: 13 Feb 2024 @ 09:30

Return: -23.53%

Previous signal: Feb 12 - 10:27

Previous signal: Sell

Return: -6.14 %

Live Chart Being Loaded With Signals

Commentary (16 Apr 2024 @ 16:00):

Stats
Today's Volume	13 581.00
Average Volume	355 669
Market Cap	7.07M
EPS	$0 ( 2024-04-01 )
Next earnings date	( $-2.40 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.120
ATR14	$0.0370 (1.02%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-11	Hoffman Lawrence R	Sell	0	Common Stock
2022-09-21	Rich Stuart	Buy	1 909 585	Common Stock
2022-09-21	Rich Stuart	Sell	1 909 585	Common Stock
2022-08-11	Doogan Declan	Sell	567 871	Common Stock
2022-06-09	Rich Stuart	Buy	100 000	Stock Option (right to buy)

INSIDER POWER
27.24
Last 92 transactions
Buy: 35 341 052 \| Sell: 26 670 670

Volume Correlation

Long: 0.03 (neutral)

Short: 0.21 (neutral)

Signal:(48.516) Neutral

Tenax Therapeutics Inc Correlation

10 Most Positive Correlations
SIRI	0.904
GBNH	0.895
FGBI	0.894
GSMG	0.892
CMLS	0.892
ALXO	0.888
RGF	0.887
GOOD	0.885
JRJC	0.885
GNTY	0.884

10 Most Negative Correlations
AMPH	-0.917
WINA	-0.917
XM	-0.908
FSLR	-0.899
ANSS	-0.898
ALTR	-0.892
INTA	-0.891
RBBN	-0.891
TYRA	-0.891
AXON	-0.89

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Tenax Therapeutics Inc Correlation - Currency/Commodity

0.36
( neutral )

0.14
( neutral )

0.00
( neutral )

0.33
( neutral )

0.66
( moderate )

-0.41
( neutral )

Tenax Therapeutics Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-7 570.00 (0.00 %)
EPS:	$-31.04

Q4	2023
Revenue:	$0
Gross Profit:	$-4 670.00 (0.00 %)
EPS:	$-10.81

Q3	2023
Revenue:	$0
Gross Profit:	$-1 000.00 (0.00 %)
EPS:	$-6.61

Q2	2023
Revenue:	$0
Gross Profit:	$-1 000.00 (0.00 %)
EPS:	$-4.00

Financial Reports:

No articles found.

Tenax Therapeutics Inc

Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.